Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009)

NCT04428151 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

408

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

DRUG: Lenvatinib
BIOLOGICAL: Pembrolizumab
DRUG: Docetaxel
DRUG: Capecitabine
DRUG: Paclitaxel
DRUG: Cetuximab
DRUG: Lenvatinib

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]